IOVANCE BIOTHERAPEUTICS Files 8-K
Ticker: IOVA · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, biotech
Related Tickers: IOVA
TL;DR
IOVA filed an 8-K on 5/31, check for updates.
AI Summary
On May 31, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in biological products and has previously operated under names like Lion Biotechnologies, Inc. and Genesis Biopharma, Inc.
Why It Matters
This filing provides an update on IOVANCE BIOTHERAPEUTICS, INC.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which typically contains standard corporate information and does not indicate immediate significant risk.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- Lion Biotechnologies, Inc. (company) — Former company name
- Genesis Biopharma, Inc (company) — Former company name
- May 31, 2024 (date) — Date of earliest event reported
FAQ
What is the primary business of IOVANCE BIOTHERAPEUTICS, INC.?
IOVANCE BIOTHERAPEUTICS, INC. is involved in Biological Products (NO DIAGNOSTIC SUBSTANCES) with SIC code 2836.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 31, 2024.
What are some of the former names of IOVANCE BIOTHERAPEUTICS, INC.?
IOVANCE BIOTHERAPEUTICS, INC. was formerly known as Lion Biotechnologies, Inc. and Genesis Biopharma, Inc.
In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
What is the business address of IOVANCE BIOTHERAPEUTICS, INC.?
The business address of IOVANCE BIOTHERAPEUTICS, INC. is 825 Industrial Road, Suite 400, San Carlos, CA 94070.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 9.4 · Accepted 2024-06-03 08:01:02
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
Filing Documents
- tm2416237d1_8k.htm (8-K) — 25KB
- tm2416237d1_ex99-1.htm (EX-99.1) — 59KB
- tm2416237d1_ex99-1img01.jpg (GRAPHIC) — 103KB
- tm2416237d1_ex99-1img02.jpg (GRAPHIC) — 523KB
- tm2416237d1_ex99-1img03.jpg (GRAPHIC) — 204KB
- tm2416237d1_ex99-1img04.jpg (GRAPHIC) — 227KB
- tm2416237d1_ex99-1img05.jpg (GRAPHIC) — 159KB
- tm2416237d1_ex99-1img06.jpg (GRAPHIC) — 130KB
- tm2416237d1_ex99-1img07.jpg (GRAPHIC) — 218KB
- tm2416237d1_ex99-1img08.jpg (GRAPHIC) — 159KB
- tm2416237d1_ex99-1img09.jpg (GRAPHIC) — 138KB
- tm2416237d1_ex99-1img10.jpg (GRAPHIC) — 123KB
- tm2416237d1_ex99-1img11.jpg (GRAPHIC) — 137KB
- tm2416237d1_ex99-1img12.jpg (GRAPHIC) — 240KB
- tm2416237d1_ex99-1img13.jpg (GRAPHIC) — 198KB
- tm2416237d1_ex99-1img14.jpg (GRAPHIC) — 175KB
- tm2416237d1_ex99-1img15.jpg (GRAPHIC) — 160KB
- tm2416237d1_ex99-1img16.jpg (GRAPHIC) — 105KB
- tm2416237d1_ex99-1img17.jpg (GRAPHIC) — 167KB
- tm2416237d1_ex99-1img18.jpg (GRAPHIC) — 205KB
- tm2416237d1_ex99-1img19.jpg (GRAPHIC) — 252KB
- tm2416237d1_ex99-1img20.jpg (GRAPHIC) — 282KB
- tm2416237d1_ex99-1img21.jpg (GRAPHIC) — 210KB
- tm2416237d1_ex99-1img22.jpg (GRAPHIC) — 186KB
- tm2416237d1_ex99-1img23.jpg (GRAPHIC) — 241KB
- tm2416237d1_ex99-1img24.jpg (GRAPHIC) — 173KB
- tm2416237d1_ex99-1img25.jpg (GRAPHIC) — 91KB
- tm2416237d1_ex99-1img26.jpg (GRAPHIC) — 137KB
- tm2416237d1_ex99-1img27.jpg (GRAPHIC) — 185KB
- tm2416237d1_ex99-1img28.jpg (GRAPHIC) — 185KB
- tm2416237d1_ex99-1img29.jpg (GRAPHIC) — 117KB
- tm2416237d1_ex99-1img30.jpg (GRAPHIC) — 168KB
- tm2416237d1_ex99-1img31.jpg (GRAPHIC) — 114KB
- tm2416237d1_ex99-1img32.jpg (GRAPHIC) — 185KB
- tm2416237d1_ex99-1img33.jpg (GRAPHIC) — 247KB
- tm2416237d1_ex99-1img34.jpg (GRAPHIC) — 168KB
- tm2416237d1_ex99-1img35.jpg (GRAPHIC) — 163KB
- tm2416237d1_ex99-1img36.jpg (GRAPHIC) — 82KB
- tm2416237d1_ex99-1img37.jpg (GRAPHIC) — 133KB
- tm2416237d1_ex99-1img38.jpg (GRAPHIC) — 186KB
- tm2416237d1_ex99-1img39.jpg (GRAPHIC) — 223KB
- tm2416237d1_ex99-1img40.jpg (GRAPHIC) — 97KB
- 0001104659-24-067485.txt ( ) — 10176KB
- iova-20240531.xsd (EX-101.SCH) — 3KB
- iova-20240531_lab.xml (EX-101.LAB) — 33KB
- iova-20240531_pre.xml (EX-101.PRE) — 22KB
- tm2416237d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On May 31, 2024, Iovance Biotherapeutics, Inc. (the "Company") updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company's presentation that it intends to use at such events, including the 2024 American Society of Clinical Oncology Annual Meeting, is attached as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Iovance Biotherapeutics, Inc., Corporate Presentation – May 31, 2024 104 Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 3, 2024 Iovance Biotherapeutics, Inc. By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO and President, and General Counsel